FO
DXCM icon

FT Options’s DexCom DXCM Stock Holding History

FT Options’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$8K Buy
+40,000
New +$707K 0.01% 192

Other funds holding DXCM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FT Options's DXCM Position: Q3 2017 in Review

FT Options opened a new position in DexCom (DXCM) in Q3 2017: 10,000 shares worth $122K. The stake represents 0.18% of the portfolio and ranks #90 among its holdings.

275 funds tracked by Wall St. Rank hold DXCM as of Q3 2017.

  • FT Options held 10,000 shares of DexCom worth $122K as of Q3 2017.
  • DexCom was a new FT Options position in Q3 2017.
  • DexCom made up 0.18% of FT Options's portfolio in Q3 2017, its #90 holding.
  • 275 funds tracked by Wall St. Rank held DexCom as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.